142 related articles for article (PubMed ID: 30031992)
1. New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent.
Desai A; Sriwastava S; Gadgeel SM; Lisak RP
J Neurol Sci; 2018 Sep; 392():100-101. PubMed ID: 30031992
[No Abstract] [Full Text] [Related]
2. Lorlatinib - Induced pulmonary arterial hypertension.
Chabrol A; Mayenga M; Hamid AM; Friard S; Salvator H; Doubre H; Fraboulet S; Metivier AC; Catherinot E; Rivaud E; Chaumais MC; Montani D; Couderc LJ; Tcherakian C
Lung Cancer; 2018 Jun; 120():60-61. PubMed ID: 29748016
[TBL] [Abstract][Full Text] [Related]
3. Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer.
Polat P; Donofrio PD
Muscle Nerve; 2016 Sep; 54(3):507. PubMed ID: 27121245
[No Abstract] [Full Text] [Related]
4. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
5. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
6. Relapsed Myasthenia Gravis after Nivolumab Treatment.
Mitsune A; Yanagisawa S; Fukuhara T; Miyauchi E; Morita M; Ono M; Tojo Y; Ichinose M
Intern Med; 2018 Jul; 57(13):1893-1897. PubMed ID: 29434145
[TBL] [Abstract][Full Text] [Related]
7. Lorlatinib induced proteinuria: A case report.
Lee CS; Wanchoo R; Seetharamu N
J Oncol Pharm Pract; 2021 Jun; 27(4):1037-1039. PubMed ID: 32996364
[TBL] [Abstract][Full Text] [Related]
8. First macrocyclic 3
Basit S; Ashraf Z; Lee K; Latif M
Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
[TBL] [Abstract][Full Text] [Related]
9. Lorlatinib for the treatment of patients with non-small cell lung cancer.
Akamine T; Toyokawa G; Tagawa T; Yamazaki K; Seto T; Takeo S; Mori M
Drugs Today (Barc); 2019 Feb; 55(2):107-116. PubMed ID: 30816885
[TBL] [Abstract][Full Text] [Related]
10. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
Caccese M; Ferrara R; Pilotto S; Carbognin L; Grizzi G; Caliò A; Brunelli M; Cuppone F; Petraglia S; Scarpa A; Tortora G; Bria E
Expert Opin Pharmacother; 2016 Dec; 17(17):2253-2266. PubMed ID: 27682212
[TBL] [Abstract][Full Text] [Related]
11. Lorlatinib Is Active in Drug-Resistant NSCLC.
Cancer Discov; 2016 Aug; 6(8):OF1. PubMed ID: 27401797
[TBL] [Abstract][Full Text] [Related]
12. Podcast on the Management of Adverse Events Associated with Lorlatinib.
Bauer TM; Bertino EM
Adv Ther; 2022 Apr; 39(4):1447-1456. PubMed ID: 35147918
[TBL] [Abstract][Full Text] [Related]
13. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer.
Loochtan AI; Nickolich MS; Hobson-Webb LD
Muscle Nerve; 2015 Aug; 52(2):307-8. PubMed ID: 25759003
[No Abstract] [Full Text] [Related]
14. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
Li W; Sparidans RW; Wang Y; Lebre MC; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2018 Oct; 143(8):2029-2038. PubMed ID: 29744867
[TBL] [Abstract][Full Text] [Related]
15. Minimal Change Disease Induced by Lorlatinib.
Betton M; Gounant V; Sannier A; Hanouna G; Goujon JM; Brosseau S; Zalcman G; Chemouny JM
J Thorac Oncol; 2018 Aug; 13(8):e154-e156. PubMed ID: 30049381
[No Abstract] [Full Text] [Related]
16. Early Onset Pulmonary Toxicity With Lorlatinib in a Patient With Previous Pulmonary Toxicity From Brigatinib.
Monzonís X; Arriola E
J Thorac Oncol; 2019 Nov; 14(11):e247-e248. PubMed ID: 31668321
[No Abstract] [Full Text] [Related]
17. Second- and third-generation ALK inhibitors for non-small cell lung cancer.
Wu J; Savooji J; Liu D
J Hematol Oncol; 2016 Mar; 9():19. PubMed ID: 26951079
[TBL] [Abstract][Full Text] [Related]
18. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
19. Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Millett RL; Elkon JM; Tabbara IA
Anticancer Res; 2018 Sep; 38(9):4969-4975. PubMed ID: 30194140
[TBL] [Abstract][Full Text] [Related]
20. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma.
Shirai T; Sano T; Kamijo F; Saito N; Miyake T; Kodaira M; Katoh N; Nishie K; Okuyama R; Uhara H
Jpn J Clin Oncol; 2016 Jan; 46(1):86-8. PubMed ID: 26491202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
